Xencor, Inc.

Hello everyone, this is the operator. Today's conference call is due to begin shortly. Until such time, your line will remain on music hold. Please continue to stand by. We thank you for your patience. Once again, today's conference call is due to begin shortly. Until such time, your line will remain on music hold. Please continue to stand by. We thank you for your patience. Thank you. Good afternoon, ladies and gentlemen, and thank you for standing by. And welcome to CENTCORE fourth quarter and full year 2021 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. Please advise that this call is being recorded at the company's request. Now, I would like to turn the call over to your speaker today, Charles Lyles, Head of Corporate Communications and Investor Relations. Thank you. Please go ahead.

Thank you, and good afternoon. Earlier today, we issued a press release which outlines the topics we plan to discuss today. The press release is available at www.zencore.com. With me on the call are Basil Dahiet, President and Chief Executive Officer, Alan Yang, Chief Medical Officer, John Desjardins, Chief Scientific Officer, and John Cush, Chief Financial Officer. After remarks, we'll open up the call for your questions. Before we begin, I would like to remind you that, during the course of this conference call, Zencore management may make forward-looking statements, including statements regarding the company's future financial and operating results, future market conditions, the plans and objectives of management, future operations, the company's partnering efforts, capital requirements, future product offerings and research and development programs. These forward-looking statements are not historical facts, but rather are based on our current expectations and beliefs and are based on information currently available to us. The outcome of the events described in these forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated by these forward-looking statements, including but not limited to those factors contained in the risk factor section of our most recently filed annual report on Form 10-K. With that, let me pass the call over to Basil.

Thanks, Charles, and good afternoon, everyone. Today we released our earnings results, and now, in a bit of a change from past calls, we'll only make a few brief comments before spending the majority of today's call on questions. We've used our array of modular protein engineering tools to create our internal development portfolio in oncology and autoimmune disease, and we used the breadth of this portfolio to take multiple simultaneous shots on goal in the clinic. The proof of concept data we generate guides which programs we advance, which we terminate, or which we partner. We focused our efforts in 2021 making key portfolio advancement decisions, specifically initiating Phase II studies for Vudalamab, our selected PD-1, CTLA-4 bispecific antibody, and prostate cancer and gynecologic tumors based on promising Phase I data. We entered a collaboration with Janssen for the development of Pomodimab, our CD20 by CD3 bispecific antibody, to add their expertise and resources to the program and enable novel combination trials in a highly competitive therapeutic area. We terminated development of vibocodamab, our CD123 by CD3, due to a challenging clinical profile and a changing treatment landscape. Of course, we're continually applying our engineering tools to build drug candidates that tackle new or hard-to-address biologies. And several of our early-stage programs are advancing into clinical studies and reporting data this year, led by our reduced-potency cytokines and our 2 plus 1 CD3 and CD28 T-cell engagers. Our goal is a well-balanced portfolio of late and early stage programs in development that we can potentially advance to approval and ultimately the market if the data supports that. Now, supporting our development work is the growing partnership portfolio, including three market products producing royalties for us, such as Citrobimab, the Veer GSK antibody for treating COVID-19. We also have a broad clinical pipeline with our partners, such as the exciting new 2 plus 1 CD3 T cell engager, AMG509, that we created for prostate cancer with our partner Amgen, in which they released early but very promising data for this month. Our own XMAP819 shares the same 2 plus 1 format and will start a clinical trial in renal cell carcinoma this year. Now we'll turn to Alan Yang, our chief medical officer, who will review a few recent highlights of our clinical programs and upcoming plans. Alan?